Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?

Bibliography

• Seidell JC. Obesity, insulin resistance and diabetes–a worldwide epidemic. Br J Nutr 2000;83(Suppl 1):S5-8
   PubMedGoogle Scholar
• Bonow RO, Smaha LA, Smith SC Jr, World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002;106:1602-5
   PubMed Web of Science ®Google Scholar
• Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011;34:1249-57
   PubMed Web of Science ®Google Scholar
• Colagiuri S, Hussain Z, Zimmet P, Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 2004;27:367-71
   PubMed Web of Science ®Google Scholar
• Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 2004;103:21-80
   PubMed Web of Science ®Google Scholar
• Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008;7:339-57
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Latest development in drug discovery on G protein-coupled receptors. Curr Protein Pept Sci 2006;7:465-70
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Hoglund PJ, Gloriam DE, Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 2003;554:381-8
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Inoue H, Kawakami S, Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem Biophys Res Commun 2006;351:474-80
   PubMed Web of Science ®Google Scholar
• Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009;58:1058-66
   PubMed Web of Science ®Google Scholar
• Lan H, Vassileva G, Corona A, GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 2009;201:219-30
   PubMed Web of Science ®Google Scholar
• Soga T, Ohishi T, Matsui T, Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005;326:744-51
   PubMed Web of Science ®Google Scholar
• Chu ZL, Carroll C, Alfonso J, A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 2008;149:2038-47
   PubMed Web of Science ®Google Scholar
• Parker HE, Habib AM, Rogers GJ, Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009;52:289-98
   PubMed Web of Science ®Google Scholar
• Cornall LM, Mathai ML, Hryciw DH, GPR119 regulates genetic markers of fatty acid oxidation in cultured skeletal muscle myotubes. Mol Cell Endocrinol 2013;365:108-18
   PubMed Web of Science ®Google Scholar
• Chu ZL, Carroll C, Chen R, N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol 2010;24:161-70
   PubMed Web of Science ®Google Scholar
• Ning Y, O'Neill K, Lan H, Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol 2008;155:1056-65
   PubMed Web of Science ®Google Scholar
• Overton HA, Babbs AJ, Doel SM, Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3:167-75
   PubMed Web of Science ®Google Scholar
• Kogure R, Toyama K, Hiyamuta S, 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion. Biochem Biophys Res Commun 2011;416:58-63
   PubMed Web of Science ®Google Scholar
• Wolfe RR, Klein S, Carraro F, Role of triglyceride-fatty acid cycle in controlling fat metabolism in humans during and after exercise. Am J Physiol 1990;258:E382-9
   PubMed Web of Science ®Google Scholar
• Chawla A, Repa JJ, Evans RM, Nuclear receptors and lipid physiology: opening the X-files. Science 2001;294:1866-70
   PubMed Web of Science ®Google Scholar
• Duplus E, Forest C. Is there a single mechanism for fatty acid regulation of gene transcription? Biochem Pharmacol 2002;64:893-901
   PubMed Web of Science ®Google Scholar
• Chu ZL, Jones RM, He H, A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148:2601-9
   PubMed Web of Science ®Google Scholar
• Katz LB, Gambale JJ, Rothenberg PL, Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin Pharmacol Ther 2011;90:685-92
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ohishi T, Matsui T, Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun 2010;400:437-41
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ohishi T, Matsui T, Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem Biophys Res Commun 2010;402:280-5
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tanaka H, Oshima H, AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun 2010;400:745-51
   PubMed Web of Science ®Google Scholar
• Semple G, Fioravanti B, Pereira G, Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 2008;51:5172-5
   PubMed Web of Science ®Google Scholar
• Nunez DJ, Lewis EW, Swan S, A study in healthy volunteers to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of GSK1292263, a novel GPR119 agonist [abstract]. 70th Annu Meet Sci Sess Am Diabetes Assoc (ADA) 2010; Diabetes, Orlando
   Google Scholar
• Yoshida S, Ohishi T, Matsui T, The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic beta-cell function. Diabetes Obes Metab 2011;13:34-41
   PubMed Web of Science ®Google Scholar
• Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 2000;5:D678-93
   PubMed Web of Science ®Google Scholar
• Jorgensen SB, Jensen TE, Richter EA. Role of AMPK in skeletal muscle gene adaptation in relation to exercise. Appl Physiol Nutr Metab 2007;32:904-11
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Haring HU. Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2010;12:1-11
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 2012;23:126-31
   PubMed Web of Science ®Google Scholar
• Gao J, Tian L, Weng G, Stimulating beta cell replication and improving islet graft function by GPR119 agonists. Transpl Int 2011;24:1124-34
   PubMed Web of Science ®Google Scholar
• Cox HM, Tough IR, Woolston AM, Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab 2010;11:532-42
   PubMed Web of Science ®Google Scholar
• Gao J, Tian L, Weng G, Stimulating beta-cell replication and improving islet graft function by AR231453, A gpr119 agonist. Transplant Proc 2011;43:3217-20
   PubMed Web of Science ®Google Scholar
• Fu J, Oveisi F, Gaetani S, Oleoylethanolamide, an endogenous PPAR-[alpha] agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005;48:1147-53
   PubMed Web of Science ®Google Scholar
• Baron AD, Brechtel G, Wallace P, Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 1988;255:E769-74
   PubMed Web of Science ®Google Scholar
• Zurlo F, Larson K, Bogardus C, Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 1990;86:1423-7
   PubMed Web of Science ®Google Scholar
• Edholm T, Cejvan K, Abdel-Halim SM, The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterol Motil 2009;21:313-21
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20
   PubMed Web of Science ®Google Scholar
• Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 2000;10:238-45
   PubMed Web of Science ®Google Scholar
• Kelley DE, Williams KV, Price JC, Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:5412-19
   PubMed Web of Science ®Google Scholar
• Kim JY, Hickner RC, Cortright RL, Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 2000;279:E1039-44
   PubMed Web of Science ®Google Scholar
• Mogensen M, Sahlin K, Fernstrom M, Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007;56:1592-9
   PubMed Web of Science ®Google Scholar
• Greco AV, Mingrone G, Giancaterini A, Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002;51:144-51
   PubMed Web of Science ®Google Scholar
• Bruce CR, Anderson MJ, Carey AL, Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J Clin Endocrinol Metab 2003;88:5444-51
   PubMed Web of Science ®Google Scholar
• Pagliassotti MJ, Gayles EC, Hill JO. Fat and energy balance. Ann N Y Acad Sci 1997;827:431-48
   PubMed Web of Science ®Google Scholar
• Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 2002;105:1861-70
   PubMed Web of Science ®Google Scholar
• Ohishi T, Yoshida S. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Investig Drugs 2012;21:321-8
   PubMed Web of Science ®Google Scholar
• Nunez DJ, Bush M, Collins D, Novel and profound lipid effects of GSK1292263, a potent and selective GPR119 agonist, in Dyslipidemic subjects [A9918. Conference Abstract]. American Heart Association Scientific Session; Circulation, Los Angeles; 2012
   Google Scholar
• Acitores A, Gonzalez N, Sancho V, Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J Endocrinol 2004;180:389-98
   PubMed Web of Science ®Google Scholar
• Villanueva-Penacarrillo ML, Martin-Duce A, Ramos-Alvarez I, Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. Regul Pept 2011;168:39-44
   PubMed Web of Science ®Google Scholar
• Cornall LM, Mathai ML, McAinch AJ. The effect of GPR119 activation on genetic regulators of nutrient metabolism in cardiac muscle myoblasts [abstract]. Australia and New Zealand Obesity Society Annual Scientific Meeting 2012; Obesity Research and Clinical Practice, Auckland. p. 52
   Google Scholar
• Coort SL, Bonen A, van der Vusse GJ, Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol Cell Biochem 2007;299:5-18
   PubMed Web of Science ®Google Scholar
• Buchanan J, Mazumder PK, Hu P, Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-9
   PubMed Web of Science ®Google Scholar
• Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 2011;1813:1351-9
   PubMed Web of Science ®Google Scholar
• Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002;34:1249-57
   PubMed Web of Science ®Google Scholar
• Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J 2011;35:437-43
   Google Scholar
• Mannucci E, Rotella CM. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutr Metab Cardiovasc Dis 2008;18:639-45
   PubMed Web of Science ®Google Scholar
• Negoro K, Yonetoku Y, Maruyama T, Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists. Bioorg Med Chem 2012;20:2369-75
   PubMed Web of Science ®Google Scholar
• Hansen HS, Rosenkilde MM, Holst JJ, GPR119 as a fat sensor. Trends Pharmacol Sci 2012;33:374-81
   PubMed Web of Science ®Google Scholar